Abbott Laboratories (NYSE: ABT) is a global healthcare company involved in diagnostics, medical devices, nutrition, and pharmaceuticals. The company is scheduled to release its first-quarter earnings report on April 16, 2026, before the market opens. This report gives investors insight into the company's recent performance.
Wall Street analysts have set an earnings per share (EPS) estimate of $1.14 for the quarter. EPS shows how much profit the company makes for each share of its stock. As highlighted by Zacks, this forecast represents a 4.60% increase from the same period last year.
Revenue estimates are approximately $11.00 billion. This figure would be a 6.40% increase from the $10.36 billion reported a year ago. Revenue is the total amount of money a company generates from its sales before any expenses are subtracted. The consensus EPS estimate has not changed in the last 30 days.
Recent company events include the completion of its acquisition of Exact Sciences (NASDAQ: EXAS) on March 23. Following this, Barclays (NYSE: BCS) maintained a positive rating on Abbott Laboratories and raised its price target to $144.00. However, as highlighted by Reuters, a jury also ordered the company to pay $53.00 million in a lawsuit concerning its infant formula.
The company's financial health shows a price-to-earnings (P/E) ratio of 27.06, which compares its share price to its earnings. Abbott Laboratories also has a low debt-to-equity ratio of 0.29, indicating it has less debt compared to its shareholder equity. Its current ratio of 1.58 suggests it can comfortably meet its short-term financial obligations.
